FTO and cancer: Given the limited efficacy of available inhibitors for DNA methylation and histone modifications in cancer therapy, “RNA epitranscriptomic drugs”, including FTO inhibitors that revert m6A mRNA epigenomes from non-responsive cells to a drug responsive state, could be uniquely positioned to either prevent or override TKI resistance.